Oruka Therapeutics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. We will get underway here. A lot to cover. Thank you very much for joining us on our next session. I am Michael Yee, Global Head of Biotech Research at UBS, and I am thrilled to have the CEO of Oruka Therapeutics, Lawrence Klein, with us. Lawrence, I was just talking with you. Congratulations on all the achievements in 2026. Had a lot of positive phase II readouts, and has propelled your stock to basically near 52-week highs, and one of the few mid-cap biotechs that is near their all-time highs, while the rest of the XBI sort of pulled back, and I think it is a testament to some of your data.
If I may just offer you the opportunity to talk a little bit about your two lead drugs, give us a backdrop of what you have shown, specifically with ORKA-001, a long-acting and I would say superior efficacy profile than AbbVie's SKYRIZI, and a second drug, which is a long-acting IL-17, which could be very competitive to BIMZELX for all those UCB folks out there. Talk about those two programs.
Yeah, great. Happy to. Thanks, Mike. Thanks for having us, and thanks everybody for joining. I think that was a great intro, set the stage. It is definitely been an action-packed 2026 for us.
Yeah. I think the headline has been the phase II data that has emerged from our 001 program.
The thesis behind Oruka was that there is one more meaningful step we can take in the product profile of biologics in psoriatic disease, primarily plaque psoriasis and psoriatic arthritis is our main focus, where IL-23p19 and IL-17A/F have really emerged as the best targets to treat that condition, and they are highly effective and very, very well tolerated. They have allowed us to reach some pretty remarkable kind of efficacy outcomes. Now the next frontier is sort of perfect the product profile, and there has been huge investments made in oral formats of these molecules that target these pathways. Those have consistently sort of fallen short of the efficacy of the best biologics, and really the appeal is a daily pill, sometimes with the food effect.
What we have is, we think, something more compelling than that, which is some of the highest levels of efficacy we've ever seen in this indication space, with the potential to dose as infrequently as once to twice per year. When we go out and do our market research, we think is a winning profile, in a market that's maybe $40 billion and growing. Just tremendous potential for these products to reward all stakeholders. With our phase II data, we've shown PASI 100, which is fully clear skin, going from a baseline of PASI score of maybe 20, which is 20%-25% of body surface area. Think of like entire torso covered in a psoriasis plaque, pretty severe disease, to complete clearance, which means a dermatologist does a full skin survey and can't find psoriasis on the body.
We have rates in the 60% at week 16, and that's actually grown to over 70 at the six-month mark with no additional dosing beyond induction. Those are basically the highest rates of efficacy that have ever been observed with any mechanism, and in the format with ORKA-001 of an IL-23, which is essentially one of the cleanest mechanisms of all of I&I. We have safety data now on over 250 subjects, which is pretty similar to placebo. To achieve those rates of efficacy, very high tolerability in a format that we'll see in December, we think could potentially be dosed once a year.
By the way, just for the context of that, as people learn this, I know there's a lot of specialists and people who have seen some of this data, but AbbVie's SKYRIZI, I cover AbbVie, which is going to do like $20 billion in SKYRIZI, their PASI 100s are between 35%-50%.
Yeah, that's right. Let's call it 45%, and you're showing 50% better, which is 60%-70%.
That's right. AbbVie's SKYRIZI is not showing that.
Yeah, about a 20 percentage point delta.
Yeah. Okay. Those PASI 100 scores have been reported out. They are a very strong step up from a very good drug, SKYRIZI. What is most important is that while you have shown good induction data and the potential for once every six-month or 12-month dosing, maintenance of those responses is also important. You have some data coming up on that. I just want to ask you what you think about that to complete the profile for this drug.
Yeah. That has always been the core of the differentiation we were shooting for with ORKA-001. Glad to see the efficacy delta. Obviously, that is very powerful. This is an extended half-life molecule with an approximately 100-day half-life. To our knowledge, that is the longest half-life of any monoclonal in all of biopharma, so it is really a special molecule that we think could get to very, very long dose intervals. We have dosed subjects in induction. We have shown data out to six months with no additional dosing that shows a continued deepening in the response. This next test in December will be 52-week data, and it will include a group of subjects that have not received a dose since their induction regimen, so basically a year out from last dose. If we can maintain a good level of response in that group, I think we can confidently say we have a once-a-year treatment.
We do want to have a six-month option on the label regardless of what the 52-week data shows. We think that is important in a preference-driven market to have flexibility around dosing. When we take that profile out and test it with physicians and patients, the response is really remarkable. We think it could really be a category-winning profile.
AbbVie's SKYRIZI has 35%-50%, let us call it 45%-50%, I will even give them the benefit of the doubt, very strong results, and it is a $20 billion drug, and that is dosed once every three months in psoriasis. When you look at those PASI 100 rates and dose once every three months, the maintenance of that at the one-year time point, meaning I guess their last dose was three months ago, they have approximately 80% of those patients at the beginning that did maintain that PASI 100.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
